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Abstract
Background: Pleuropulmonary blastoma (PPB) is a rare childhood dysontogenetic intrathoracic
neoplasm associated with an unfavourable clinical behaviour.
Cases presentation: We report pathological and cytogenetic findings in two cases of PPB at
initial diagnosis and recurrence. Both tumors were classified as type III pneumoblastoma and
histological findings were similar at diagnosis and relapse. In both cases, conventional cytogenetic
techniques revealed complex numerical and structural chromosomal abnormalities. Molecular
cytogenetic analysis (interphase/metaphase FISH and multicolor FISH) identified accurately
chromosomal aberrations. In one case, TP53 gene deletion was detected on metaphase FISH. To
date, only few cytogenetic data have been published about PPB.
Conclusion:  The PPB genetic profile remains to be established and compared to others
embryonal neoplasia. Our cytogenetic data are discussed reviewing cytogenetics PPBs published
cases, illustrating the contribution of multicolor FISH in order to identify pathogenetically
important recurrent aberrations in PPB.
Background
Pleuropulmonary pneumoblastoma (PPB) is a rare and
aggressive form of childhood's malignancy [1]. PPB exhib-
its unique histological, biological and clinical characteris-
tics. The term PPB was first proposed by Manivel et al [2].
Histologically, it is characterized by primitive blastemal
and mesenchymal elements and lack of malignant epithe-
lial elements. Three histopathological subtypes are
described [3]: Type I PPB is exclusively cystic, type II PPB
presents intermediate features between purely cystic and
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solid PPB and type III PPB is a solid tumor without epithe-
lial-lined cystic spaces.
PPB cases can occur within a family environment but PPB
has not been described as a well-defined component of a
familial childhood cancer/constitutional disease [1,4].
The clinical behavior of this neoplasia remains unpredict-
able. Despite aggressive multimodal treatment combined
with chemotherapy and surgical resection, prognosis of
PPB is poor.
We report pathological and cytogenetic findings in two
cases of PPB at initial diagnosis and at recurrence. Com-
plex karyotypes were found in case 1 at recurrence and in
case 2 at diagnosis. Conventional and molecular cytoge-
netic techniques were performed and showed complex
chromosomal rearrangements.
Cases presentation
Clinical data
Case 1
A 3-year-old girl had been treated for a type III left PPB in
another institution. Initial treatment included surgical
removal of the tumor together with 9 courses of chemo-
therapy in line with to the SIOP MMT95.3B recommenda-
tions containing vincristine, adriamycine, carboplatin,
etoposide, actinomycin D and ifosfomide. Four years
later, she developed, over a week increased vomiting and
headaches. A computed tomography of the brain showed
a large parietal lobe mass. After performing cerebral and
medullar MRI, surgical removal of the tumor was per-
formed. Postoperative computed tomography of the brain
showed no residual tumor. Additional exploration for
metastasis was negative. Histological diagnosis was PPB
type III. She had since received 4 courses of chemotherapy
and cerebral radiotherapy was planned to complete treat-
ment. She relapsed 3 months later and was treated with
gammaknife radiosurgery. 6 weeks after radiosurgery
another cerebral localized relapse occurred. Surgery was
performed and another tumour was found on a cerebral
MRI 2 months after surgery despite chemotherapy with
weekly Navelbine and daily Endoxan. She died shortly
after the disease worsened.
Case 2
A 4-year old boy was transferred to our department for
examination of the left pulmonary mass. Exploratory tests
for metastasis were negative. Surgical removal of the
tumor was performed. Histological diagnosis was PPB
type III. He was treated according to the SIOP MMT95.3B.
29 months after completion of the treatment, routine
computed tomography of the lungs showed a left paracar-
diac mass. Additional tests for metastasis were negative.
The mass was surgically removed and histological analysis
of the mass lead to the diagnosis of recurrence of type III
PPB. The boy is currently being treated with chemother-
apy and radiotherapy.
Pathology
Tumor specimens were put in formalin and paraffin-
embedded for histologic and immunohistochemical anal-
ysis. Paraffin-embedded tissues were sectioned at 4 µm
and stained with hematoxylin-phloxin-safron (HPS). For
immunohistochemistry the sections were deparaffined
and subjected to antigen retrieval. An automated immu-
nohistochemistry was performed with avidin-biotin-per-
oxidase complex on a Ventana 320 device (Tucson, AZ,
USA) with a Ventana kit (Strasbourg, France) including
AEC reagent. The following primary antibodies (dilution
and source in parentesis) were used : glial fibrillary acidic
protein (GFAP, Dakopatts, 1/2000), S-100 protein (Dako-
patts, 1/400), alpha-smooth actin (Dakopatts, predi-
luted), desmin (Immunotech, prediluted), myogenin
(Microm, 1/5).
Conventional and molecular cytogenetic analysis
Chromosome analysis was performed on tumor frag-
ments obtained from the primary (case2) or recurrent
tumors (case1 and 2). For the culture, fragments of sterile
tumor tissue were dissociated enzymatically using an
RPMI medium containing 0.02% collagenase type II and
incubated at 37°C for approximately 1 hour. A cell sus-
pension obtained after centrifugation was sown over 25
cm2 tissue culture Falcon flasks with RPMI medium sup-
plemented with 10% fetal bovine serum and antibiotics.
The cells were then incubated at 37°C in a 5% CO2
atmosphere. After the culture entered exponential growth
(10 days), chromosomal analysis was carried out using a
routine cytogenetic technique. The R-banding technique
was used for chromosomal identification. The description
of the karyotypes and criteria for clonality follow the rec-
ommendations of the International System of Human
Cytogenetic Nomenclature (ISCN 1995) [5].
Multicolor fluorescence in situ hybridization (M-FISH)
was performed on chromosome preparations from tumor
cells. The M-FISH technique was carried out as described
by the manufacturer's protocols (Metasystems, Alt-
lussheim, Germany).
For verification and further delineation of the M-FISH
findings, Locus-Specific (LSI) and Enumeration (CEP)
FISH probes (Vysis, Downers-Grove, IL, USA) were
applied to characterize chromosomal abnormalities
according the manufacturer's protocols. TP-53, CEP17,
CEP8, C-MYC and MYC-N probes were used.BMC Cancer 2006, 6:4 http://www.biomedcentral.com/1471-2407/6/4
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Results
Pathological findings
On microscopic examination, both tumors were found to
be made of solid sheets of immature cells (figures 1, 2a),
some of which were being multinucleated (figure 2d).
Mitoses were numerous and necrosis was also present. No
cystic area was noted. In case n°1, immunohistochemistry
was negative for GFAP and S100 protein. That ruled out a
malignant glioma. Myogenic markers were also negative.
In case n°2, at the time of the first surgery, a malignant
mesenchymal component showing multidirectional dif-
ferenciation was found to be associated with the blastema.
Areas containing immature cartilage and rhabdomyoblas-
tic cells were present. The myogenic differenciation was
confirmed by immunohistochemistry. Some cells were
positive for desmin and myogenin (figure 2b, 2c). At
recurrence case n°2 only showed areas of poorly differen-
ciated blastematous cells (figure 2d). Pathological diagno-
sis in both cases was PPB type III.
Cytogenetic data
Case 1
At diagnosis no metaphases were found after culture and
no frozen material was made available for retrospective
molecular cytogenetic techniques.
At recurrence, cytogenetic study showed an abnormal and
complex karyotype [Figure 3a]. In line with the cytoge-
netic analysis, we carried out M-FISH [Figure 3b] and met-
aphase in situ hybridization with CEP 8 probe. We
identified an unbalanced translocation between chromo-
some 8 and 18. The der(8)t(8;18) showed a likely dupli-
cation of the 8q11q12 region [Figure 3c]. Metaphase FISH
with CEP17 and TP53 probes showed a TP53 deletion on
der(17) identified by M-FISH [Figure 3d]. A dicentric
chromosome dic(11;21) with loss of a segment of the
short arm of chromosome 11 was revealed. FISH analysis
with the MYCN and MYCC probes did not show showed
amplification of both oncogenes (data not shown).
The cytogenetic result was:
38~44,X,-
X,der(8)t(8;18)(p1?;q1?),dic(11;21)(p11;p11),-
15,der(17)t(15;17)(q1?;p1?3),-18,del(20)(p12pter)
[cp11]/81~82<4n>,idemx2 [cp2]/46,XX[7].ish
der(8)t(8;18)
(D8Z1+,wcp8+,wcp18+),dic(11;21)(wcp11+,wcp21+),de
r(17)t(15;17)(D17Z1+, wcp15+,wcp17+,TP53-)
Case 2
At diagnosis, conventional cytogenetic study showed a
complex hyperdiploid karyotype (modal number: 91)
[Figure 4a]. M-FISH analysis specified complex structural
chromosomal abnormalities [Figure 4b].
The cytogenetic result was:
80~109<4n>,XXYY,+X,der(1)t(1;8)(p1?;q1?)x2,dup(3)(?
q)x2,+der(?4)t(1;4),-5,dup(7) (q?),+8,-9,der(9)t(9;13),-
10,-10,-11,-16,-17,der(19)t(10;19)x2 [cp8]/46,XY[7] .ish
der(1)t(1;8)(wcp1+,wcp8+),dup(3)(?q)(wcp3+),der(?4)t
(1;4)(wcp1+,wcp4+),dup(7)(q?)
(wcp7+),t(9;13)(wcp9+,wcp13+),t(10;19)(wcp10+,wcp1
9+)
At recurrence karyotype was normal: 46, XY [20]. In order
to carry out abnormal clone unidentified by conventional
cytogenetic technique, molecular techniques were per-
formed on nuclei by interphase FISH technique using
chromosome 8 centromeric region probe. Overrepresen-
tation (8 to 10 signals) of centromeric region of chromo-
some 8 was confirmed in 32% of interphase nuclei by in
situ  hybridization staining allowing us evoke a related
clone (probably a doubled population) from initial
tumor [Figure 4c].
Conclusion
PPB is among the rarest pediatric malignancies. The out-
come is particularly unfavourable because of recurrence
and/or metastases. The central nervous system represents
the main site of metastases [1,6-8].
Only 23 cases with cytogenetic analysis (conventional
and/or molecular) have been reported [Additional file 1].
Most of them revealed complex numerical and structural
chromosomal abnormalities such as recurrent aneuploidy
of chromosome 2 and 8 and structural rearrangement of
various chromosomes [9-22]. Interestingly, in 4 cases with
Case n°1: Histology (HES × 100) Figure 1
Case n°1: Histology (HES × 100). At recurrence: poorly dif-
ferentiated blastematous cells with pleiomorphic component.BMC Cancer 2006, 6:4 http://www.biomedcentral.com/1471-2407/6/4
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conventional cytogenetic studies on a total of 13 cases
published, karyotypic description was incomplete (pres-
ence of unidentified marker chromosome) [Additional
file 1: cases 7, 10, 12 and 18]. Only one case was analyzed
by multicolor spectral karyotyping [Additional file 1: case
9].
Both cases we report here represent additional cases stud-
ied by conventional and molecular cytogenetic tech-
niques (FISH and M-FISH).
Data found in literature corroborate numerical gains of
chromosome 8 as the main recurrent chromosomal
abnormality in PPB (22 cases published) [9-13,15-22].
Thus, it may represent a primary event in the genesis of
PPB [12]. Few data are available about structural abnor-
malities of chromosome 8. The two cases we report here
showed structural aberration of the either long or short or
both arms of chromosome 8 identified by M-FISH. Three
other cases showed rearrangement of the long arm of
chromosome 8 [Additional file 1 : cases 4, 6 and 18]. Fur-
ther studies are required to clarify the role of chromosome
8 and to come up with candidate genes in PPB pathogen-
esis. For instance, PLAG1 which specifically activates tran-
scription is of the highest interest. Indeed, it is involved in
the genesis of another embryonal tumour: lipoblastomas,
mesenchymal and epithelial neoplasia [23,24].
Amongst pediatric tumors, mutations in TP53 gene have
been described in sporadic Wilm's tumor, embryonal
rhadomyosarcoma and in hepatoblastoma and seemed to
be associated with a poor prognosis [25]. However, muta-
tions in the TP53 gene are found in a large proportion of
adult cancers but are not considered to be specific events
of childhood embryonal tumors. In PPB, only one case of
TP53  deletion was identified by molecular cytogenetic
technique [20] but five cases showed a structural rear-
rangement on 17p [Additional file 1: cases n° 2, 4, 7, 11
and 18]. In these cases, TP53 status was not mentioned.
Furthermore, Kusafuka et al., using PCR-SSCP method in
2 patients, raised the possibility that p53 inactivation is
involved in the pathogenesis and outcome of PPB [26]. In
our first case, the TP53 gene deletion results in the loss of
17p11pter chromosomal region by an unbalanced trans-
location t(15;17) [Figure 3d]. The same pattern may be
identified in the case of Kelsey et al. with a subsequent loss
of 17p material deletion and an unbalanced t(8;17) [12].
This last case was particularly interesting because a clonal
evolution was demonstrated from a clone with a trisomy
8 to a clone with a translocation event with a chromo-
some 17 der(17)t(8;17)(q11.2, p13.1) resulting in a tri-
somy for the long arm of chromosome 8 and a
monosomy for the distal region of chromosome 17 sug-
gesting TP53 deletion is a secondary change of importance
in the progression of the neoplasia.
Two cases studied by conventional cytogenetic showed a
structural rearrangement of the short arm of chromosome
11: a der(11)t(7;11)(q11.2;p11.2) and a
dup(11)(p13p15) [Additional file 1: cases 2, 4]. In our
first case, we observed a dicentric chromosome dic(11;21)
associated with the loss of chromosomal region
11(p11pter). 11p deletion occurred in 38% of cases of
nephroblastoma (Wilm's tumor). Two genes seem to be
implicated: WT1 gene at 11p13 and WT2 gene at 11p15
[10,25]. Polymorphism studies showed loss of heterozy-
gosity at 11p13 in 72% of primary embryonal rhabdomy-
osarcoma [27]. In hepatoblastoma, the region associated
with Beckwith-Wiedmann syndrome 11p15.5 could play
a role in the development of neoplasia [25]. Although no
LOH of markers on 11p13 and 11p15 studies are pub-
lished to date for PPB, Priest et al. suggest a common
genetic pathway among embryonal tumors involving
chromosomal region 11p [10]. These authors suggested
that PPB should be regarded as a pulmonary dysontoge-
netic similar to nephroblastoma (Wilm's tumor), neurob-
lastoma, hepatoblastoma or embryonal
rhabdomyosarcoma [10]. Comparative Genomic Hybrid-
ization (CGH) findings reported by Roque et al. support
the hypothesis that PPB may be tumorigenetically related
to embryonal rhabdomyosarcoma [22].
Similarly, Bonner et al. demonstrated that transcriptome
wide analysis of gene expression by DNA array technology
showed numerous patterns associated with lung develop-
ment in murines. The authors concluded that the genes
Case n°2: Histology (HES × 20) Figure 2
Case n°2: Histology (HES × 20). At diagnosis: poorly differ-
entiated blastematous cells with cartilage (2a). Cytoplasmic 
desmin (2b) and nuclear myogenin (2c) are observed within 
the tumor cells. Histology (HES × 100): At recurrence only 
blastematous areas are observed (2d).BMC Cancer 2006, 6:4 http://www.biomedcentral.com/1471-2407/6/4
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Conventional and molecular cytogenetic data of case 1 at recurrence Figure 3
Conventional and molecular cytogenetic data of case 1 at recurrence. 3a: R-banded karyotype: arrows indicate structural 
clonal abnormalities. 3b: Partial R-banded details associated with partial Multiplex FISH results of each structural chromosomal 
abnormality. Painting chromosomes by M-FISH are showed in false color view with fluorescence profiles. 3c: Partial metaphase 
in situ hybridization with a chromosome 8 centromeric probe directly labelled FITC showing one normal chromosome 8 (fine 
arrow) and one der(8) (thick arrow). 3d: Partial metaphase in situ hybridization with a TP53 probe directly labelled Spectrum 
Orange (SO) and a chromosome 17 centromeric probe directly labelled FITC. This partial metaphase shows one normal chro-
mosome 17 with both FITC and SO fluorescent signals (fine arrow) and one der(17) with an isolated FITC fluorescent signal 
(thick arrow) indicating a P53 gene deletion.BMC Cancer 2006, 6:4 http://www.biomedcentral.com/1471-2407/6/4
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Conventional and molecular cytogenetic data of case 2 at diagnosis and recurrence Figure 4
Conventional and molecular cytogenetic data of case 2 at diagnosis and recurrence. 4a: R-banded karyotype from initial tumor 
characterized by complex numerical and structural clonal abnormalities. Arrows indicate structural clonal aberrations. 4b: Par-
tial R-banded details associated with partial Multiplex FISH results of each structural chromosomal abnormality. Painting chro-
mosomes by M-FISH are showed in false color view with fluorescence profiles. 4c:Interphase in situ hybridization with a 
chromosome 8 centromeric probe directly labelled FITC from recurrent tumor showing over representation (10 signals) of 
centromeric region of chromosome 8 : nuc ish 8 cen (D8Z1x10).BMC Cancer 2006, 6:4 http://www.biomedcentral.com/1471-2407/6/4
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identified as relevant to lung development and belonging
to three regulatory pathways (Wnt/β-catenin signalling,
cell cycle and apoptosis) may be suggested as candidate
susceptibility genes for lung tumorigenesis [28]. Chromo-
some 1p alterations harboring developmental genes
related to the Notch and Wnt pathways have been
reported also by Garnis et al [29]. Further similar studies
in embryonal tumors could be proposed to contribute to
our understanding of unusual characteristics in the PPB
development.
Chromosomal instability appears to be characteristic of
this tumor. Identification by M-FISH technique allowed
the identification of recurrent complex structural chromo-
somal abnormalities. Furthers collegial studies, regroup-
ing PPB cases as in the PPB Registry by Priest and
colleagues [30], are required to identify specific chromo-
somal rearrangements providing a better understanding
about the molecular pathogenesis of this aggressive
tumor.
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